Soleno Therapeutics (SLNO): Rethinking Valuation After Unexpected Q3 Profit Turnaround
Simply Wall St 08/11 12:38
Goldman Sachs Maintains Sell on Cytek Biosciences, Lowers Price Target to $3
Cytek BioSciences +1.76%
Cytek BioSciences CTKB | 0.00 |
Goldman Sachs analyst Matthew Sykes maintains Cytek Biosciences (NASDAQ:
CTKB) with a Sell and lowers the price target from $3.5 to $3.
Recommend
10x Genomics (TXG): How Fresh Results and New Guidance Are Shaping Its Valuation
Simply Wall St 08/11 13:23Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Simply Wall St 08/11 13:56Revvity (RVTY): Evaluating Valuation After Q3 Results, New Guidance, and $1 Billion Share Buyback Announcement
Simply Wall St 09/11 03:36How NeoGenomics' Q3 Results and Liquid Biopsy Advances Will Impact NEO Investors
Simply Wall St 09/11 13:28Illumina, Inc. (NASDAQ:ILMN) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected
Simply Wall St 09/11 14:07Why Adaptive Biotechnologies (ADPT) Is Up After Raising MRD Revenue Guidance and Returning to Profitability
Simply Wall St 09/11 14:37Could Qiagen's (QGEN) Leadership Change Reveal Shifts in Its Long-Term Growth Priorities?
Simply Wall St 09/11 18:24
